Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Pfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag still seems too much for many heart patients.